Sexual deviance among male college students: prior deviance as an explanation

Much research on sexual deviance on university and college campuses is limited by its narrow focus on group affiliation and leads to much speculation and conjecture. This article suggests that an alternative explanation is more suitable for explaining such an important and complex problem on college campuses. It argues that prior deviance serves as a more robust predictor variable of sexual deviance. Logistic regression analyses indicate a direct relationship between prior deviance and sexual deviance. The results lend support to the argument that group affiliation is not a suitable explanation for such a complex societal problem-sexual deviance. Limitations of the study and directions for future research on sexual deviance are discussed.     

The Indiana University Advanced Research and Technology Institute: A Case Study

The Indiana University Advanced Research and Technology Institute (ARTI) is the technology transfer organ of the Indiana University system. ARTIs structure is complex, and has been dynamic since its creation in 1996. This complexity stems in part from the diversity represented by the Indiana University system and from competing interests within the university itself. In addition to the intrinsic value of higher education, the university has the potential to add substantial value to Indianas economic landscape through technology transfer, economic development initiatives and the resulting job creation, but realizing that potential will require effectively leveraging a disconnected network including the IU campuses and critical capabilities contributed by the states other world class institutions. This paper reviews the formation of ARTI, a discussion of its structure and evolving mission, recent initiatives and some possible metrics for technology transfer initiatives.     

Managing generic competition and patent strategies in the pharmaceutical industry

Legal context: The income streams of originating pharmaceutical manufacturersare under pressure as never before, from increasing R&Dcosts, regulatory pressures, and competition from generic manufacturers.This article examines the various strategies which originatingpharmaceutical manufacturers have adopted in response to thesethreats. Key points: The authors consider various strategies, including SupplementaryProtection Certificates, life-cycle management (‘evergreening’),second pharmaceutical use claims, trade marks, and the use ofdata exclusivity and interim injunctions, in order to prolongthe protection given to existing products, and to manage competitionfrom generic manufacturers. Practical significance: The authors also include two real-life case studies in orderto illustrate the practical applications of the strategies discussedin the article.